Advertisement
Advertisement
CSTL
Castle Biosciences, Inc. Common Stock
21.12
USDSponsored
+0.87
+4.30%
Jun 18, 16:00 UTC -4
Closed
After-Market
21.08
-0.04
-0.19%
CSTL Earnings Reports
Positive Surprise Ratio
CSTL beat 22 of 28 last estimates.
79%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$87.98M
/-$0.40
Implied change from Q1 26 (Revenue/ EPS)
+5.14%
/-18.37%
Implied change from Q2 25 (Revenue/ EPS)
+2.08%
/-366.67%
Castle Biosciences, Inc. Common Stock earnings per share and revenue
On May 06, 2026, CSTL reported earnings of -0.49 USD per share (EPS) for Q1 26, beating the estimate of -0.49 USD, resulting in a 1.96% surprise. Revenue reached 83.68 million, compared to an expected 81.00 million, with a 3.30% difference. The market reacted with a -22.26% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 9 analysts forecast an EPS of -0.40 USD, with revenue projected to reach 87.98 million USD, implying an decrease of -18.37% EPS, and increase of 5.14% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Therapeutics Inc. Common Stock
Report Date
Jun 15, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.43
Surprise
+10.32%
Prenetics Global Limited Class A Ordinary Share
Report Date
Jun 10, 2026 For Q1 26
Estimate
-$1.10
Actual
-$1.61
Surprise
-45.36%
Anixa Biosciences, Inc.
Report Date
Jun 10, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.07
Surprise
+21.61%
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
FAQ
What were Castle Biosciences, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Castle Biosciences, Inc. Common Stock reported EPS of -$0.49, beating estimates by 1.96%, and revenue of $83.68M, 3.3% above expectations.
How did the market react to Castle Biosciences, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -22.26%, changed from $24.75 before the earnings release to $19.24 the day after.
When is Castle Biosciences, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Castle Biosciences, Inc. Common Stock's next earnings report?
Based on 9
analysts, Castle Biosciences, Inc. Common Stock is expected to report EPS of -$0.40 and revenue of $87.98M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement